Discover
XLO
Xilio Therapeutics, Inc.
9.13
2 x 6.79
2 x 11.64
bid
ask
+
0.09
1.00%
2 @ 04:10 PM
9.13 +0.00 (0.00%)
| Ytd | 1.90% | |
| 1y | -14.51% |
8.94
day range
9.67
7.14
52 week range
12.08
| Open | 8.99 | Prev Close | 9.04 | Low | 8.94 | High | 9.67 | Mkt Cap | 60.08M |
| Vol | 22.94K | Avg Vol | 27.85K | EPS | -0.32 | P/E | N/A | Forward P/E | -1.91 |
| Beta | -0.20 | Short Ratio | 0.42 | Inst. Own | 29.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 9.03 | 200-d Avg | 8.63 | 1yr Est | 4.50 |
| Income Statement | |||
| Total Revenue | 18.69M | ||
| Revenues (USD) | 18.69M | ||
| Gross Profit | 18.69M | ||
| Operating Expenses | 22.18M | ||
| Research and Development Expense | 14.56M | ||
| Selling, General and Administrative Expense | 7.62M | ||
| Operating Income | -3.49M | ||
| Net Income | -6.37M | ||
| Net Income Common Stock | -6.37M | ||
| Net Income Common Stock (USD) | -6.37M | ||
| Consolidated Income | -6.37M | ||
| Earnings per Basic Share | -0.33 | ||
| Earnings per Basic Share (USD) | -0.33 | ||
| Earnings per Diluted Share | -0.33 | ||
| Earning Before Interest & Taxes (EBIT) | -6.37M | ||
| Earning Before Interest & Taxes (USD) | -6.37M | ||
| Weighted Average Shares | 19.40M | ||
| Weighted Average Shares Diluted | 19.40M | ||
| Balance Sheet | |||
| Cash and Equivalents | 137.86M | ||
| Cash and Equivalents (USD) | 137.86M | ||
| Trade and Non-Trade Receivables | 6.00M | ||
| Current Assets | 145.47M | ||
| Property, Plant & Equipment Net | 6.97M | ||
| Total Assets | 154.25M | ||
| Debt Current | 1.43M | ||
| Total Debt | 6.30M | ||
| Current Liabilities | 34.20M | ||
| Debt Non-Current | 4.88M | ||
| Total Liabilities | 81.99M | ||
| Accumulated Retained Earnings (Deficit) | -434.69M | ||
| Shareholders Equity | 72.26M | ||
| Shareholders Equity (USD) | 72.26M | ||
| Assets Non-Current | 8.79M | ||
| Total Debt (USD) | 6.30M | ||
| Deferred Revenue | 35.32M | ||
| Liabilities Non-Current | 47.79M | ||
| Trade and Non-Trade Payables | 2.32M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 331.00K | ||
| Net Cash Flow from Financing | 4.49M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -14.29M | ||
| Capital Expenditure | -19.00K | ||
| Issuance (Purchase) of Equity Shares | 4.49M | ||
| Net Cash Flow from Investing | -19.00K | ||
| Net Cash Flow from Operations | -18.76M | ||
| Share Based Compensation | 1.60M | ||